A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
CSWYY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.07
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of China Shineway Pharmaceutical Group was 0.07. The lowest was 0.00. And the median was 0.04.
CSWYY's Debt-to-Equity is ranked better than 84.83% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs CSWYY: 0.04
China Shineway Pharmaceutical Group (OTCPK:CSWYY) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
China Shineway Pharmaceutical Group Debt-to-Equity Related Terms
China Shineway Pharmaceutical Group Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Debt-to-Equity Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group (CSWYY) has a Debt-to-Equity of 0.04 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on China Shineway Pharmaceutical Group and its competitors. This is near median its historical median of 0.04. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #123 out of 811 companies in the Drug Manufacturers industry, placing it in the top 15.2%.
Is China Shineway Pharmaceutical Group's Debt-to-Equity too high?
China Shineway Pharmaceutical Group's current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. The Drug Manufacturers industry median Debt-to-Equity is 0.27. China Shineway Pharmaceutical Group's value of 0.04 is 85.2% below this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #123 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #123 out of 811 companies for Debt-to-Equity. This places China Shineway Pharmaceutical Group in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. China Shineway Pharmaceutical Group's value of 0.04 is 85.2% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.27, China Shineway Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Debt-to-Equity of 0.04 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Debt-to-Equity of 0.04. The stock's GF Value™ is $17.03, compared to a current price of $19.25 — trading 13% above its estimated fair value. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 85.2% below the Drug Manufacturers industry median of 0.27. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Debt-to-Equity is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 13% above its estimated GF Value™ of $17.03.
Key valuation signals for CSWYY:
Debt-to-Equity: 0.04 (near median its 10-year median of 0.04)
GF Value™: $17.03 vs. price of $19.25 (13% above fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#123 of 811)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
